Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447473 · ClinicalTrials.gov registry record · Phase 2
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00447473 is a Phase 2 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 31 participants.
The verdict
NCT00447473, a Phase 2 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This trial represents an attempt to offer second line immunotherapy plus chemotherapy to patients who have failed prior taxane base therapy.
Interventions
- DRUG Mitoxantrone
- DRUG GM-CSF
- DRUG Ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447473
The ClinicalTrials.gov registry entry for NCT00447473 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Mitoxantrone is the first listed.
NCT00447473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447473 about?
NCT00447473 is a clinical study titled "Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer". This trial represents an attempt to offer second line immunotherapy plus chemotherapy to patients who have failed prior taxane base therapy.
What is the current status of trial NCT00447473?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2006-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00447473?
The interventions under investigation include: Mitoxantrone (DRUG), GM-CSF (DRUG), Ketoconazole (DRUG).
Who is sponsoring clinical trial NCT00447473?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.